Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction

Experimental Gerontology

Volumn 37, Issue 10-11, 2002, Pages 1175-1187

  Trougakos, Ioannis P ^a   Poulakou, Maria ^a   Stathatos, Marios ^a,b   Chalikia, Anastasia ^b   Melidonis, Andreas ^b   Gonos, Efstathios S ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

Author keywords

Aging; Atherosclerosis; Clusterin apolipoprotein J; Coronary heart disease; Diabetes; Myocardial infarction

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; CLUSTERIN; HEPARIN; CHAPERONE; CLU PROTEIN, HUMAN; GLYCOPROTEIN;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; IMMUNOBLOTTING; IN VIVO STUDY; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CELL AGING; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; EVALUATION; METHODOLOGY; STANDARD;

ANALYSIS OF VARIANCE; CELL AGING; CLUSTERIN; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; MALE; MOLECULAR CHAPERONES; MYOCARDIAL INFARCTION;

EID: 0036814405     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0531-5565(02)00139-0     Document Type: Conference Paper

References (50)

1. Bailey R.W., Dunker A.K., Brown C.J., Garner E.C., Griswold M.D. Clusterin, a binding protein with a molten globule-like region. Biochemistry. 40:2001;11828-11840.
2. Bartl M.M., Luckenbach T., Bergner O., Ullrich O., Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp. Cell Res. 271:2001;130-141.
3. Benfante R., Reed D., Frank J. Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged. Comparisons of relative and attributable risks. Ann. Epidemiol. 2:1992;273-282.
4. Bennett M.R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41:1999;361-368.
5. Bennett M.R., Boyle J.J. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis. 138:1998;3-9.
6. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496.
7. Bettuzzi S., Strocchi P., Marinelli M., Astancolle S., Davalli P., Corti A. Gene relaxation and aging: changes in the abundance of rat ventral prostate SGP-2 (clusterin) and ornithine decarboxylase mRNAs. FEBS Lett. 348:1994;255-258.
8. Burkey B.F., Stuart W.D., Harmony J.A.K. Hepatic apolipoprotein J is secreted as a lipoprotein. J. Lipid Res. 33:1992;1517-1526.
9. Calero M., Rostagno A., Matsubara E., Zlokovic B., Frangione B., Ghiso J. Apolipoprotein J (Clusterin) and Alzheimer's disease. Microsc. Res. Tech. 50:2000;305-315.
10. Choi N.H., Tobe T., Hara K., Yoshida H., Tomita M. Sandwich ELISA assay for quantitative measurement of SP-40,40 in seminal plasma and serum. J. Immunol. Meth. 131:1990;159-163.
11. Choi-Miura N.H., Sakamoto T., Ohtaki S., Nakamura H., Ishizawa S., Takagi Y. Elevated complement activities of sera from patients with high density lipoprotein deficiency (Tangier disease): the presence of normal level of clusterin and the possible implication in the atherosclerosis. Clin. Exp. Immunol. 93:1993;242-247.
12. Denke M.A., Grundy S.M. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann. Int. Med. 112:1990;780-792.
13. Dumont P., Chainiaux F., Eliaers F., Petropoulou C., Remacle J., Koch-Brandt C., Gonos E.S., Toussaint O. Overexpression of apolipoprotein J in human fibroblasts protects against cytotoxicity and premature senescence induce by ethanol and tert-butylhydroperoxide. Cell Stress Chaperones. 7:2002;23-35.
14. Gallotta G., Iazzetta N., Milan G., Ruocco A., Napoli C., Postiglione A. Prevalence of peripheral arterial disease in an elderly rural population of southern Italy. Gerontology. 43:1997;289-295.
15. Gelissen I.C., Hochgrebe T., Wilson M.R., Easterbrook-Smith S.B., Jessup W., Dean R.T., Brown A. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem. J. 331:1998;231-237.
16. Gonos E.S., Burns J.S., Mazars G.R., Kobrna A., Riley T.E.W., Barnett S.G., Zafarana G., Ludwig R.L., Ikram Z., Powell A.J., Jat P. Rat embryo fibroblasts immortalized with Simian Virus 40 T antigen undergo senescence upon its inactivation. Mol. Cell. Biol. 16:1996;5127-5138.
17. Gonos E.S., Derventzi A., Kveiborg M., Agiostratidou G., Kassem M., Clark B.F.C., Jat P.S., Rattan S.I.S. Cloning and identification of genes that associate with mammalian senescence. Exp. Cell Res. 240:1998;66-74.
18. Harlow E., Lane D. Using Antibodies: a Laboratory Manual. Second ed:1999;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
19. Holm P., Korsgaard N., Shalmi M., Andersen H.L., Hougaard P., Skouby S.O., Stender S. Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits. J. Clin. Invest. 100:1997;821-828.
20. Ishikawa Y., Akasaka Y., Ishii T., Komiyama K., Masuda S., Asuwa N., Choi-Miura N.-H., Tomita M. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler. Thromb. Vasc. Biol. 18:1998;665-672.
21. Ishikawa Y., Ishii T., Akasaka Y., Masuda T., Strong J.P., Zieske A.W., Takei H., Malcom G.T., Taniyama M., Chio-Miura N.-H., Tomita M. Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis. 158:2001;215-225.
22. Jenne D.E., Tschopp J. Clusterin: the intriguing guises of a widely expressed glycoprotein. Trends Biochem. Sci. 17:1992;154-159.
23. Jenne D.E., Lowin B., Peitsch M.C., Böttcher A., Schmitz G., Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J. Biol. Chem. 266:1991;11030-11036.
24. Jordan-Starck T.C., Lund S.D., Witte D.P., Aronow B.J., Ley C.A., Stuart W.D., Swertfeger D.K., Clayton L.R., Sells C.A., Paigen B., Harmony J.A.K. Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J. Lipid Res. 35:1994;194-210.
25. Kelso G.J., Stuart W.D., Richter R.J., Furlong C.E., Jordan-Starck T.C., Harmony J.A.K. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry. 33:1994;832-839.
26. Kim B.M., Han Y.M., Shin Y.J., Min B.H., Park I.S. Clusterin expression during regeneration of pancreatic islet cells in streptozotocin-induced diabetic rats. Diabetologia. 44:2001;2192-2202.
27. Koch-Brandt C., Morgans C. Clusterin: a role in cell survival in the face of apoptosis? Prog. Mol. Subcell. Biol. 16:1996;130-149.
28. Li P.F., Maasch C., Haller H., Dietz R., von Harsdorf R. Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation. 100:1999;967-973.
29. Mackness B., Hunt R., Durrington P.N., Mackness M.I. Increased immunolocalization of paraoxonase, clusterin and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;1233-1238.
30. Melidonis A., Dimopoulos V., Lempidakis E.M., Hatzisavas J., Kouvaras J., Stefanidis A.L., Foussas A.S. Angiographic study of coronary artery disease in diabetic patients in comparison with non-diabetic patients. Angiology. 50:1999;997-1006.
31. Melidonis A., Stefanidis A.L., Tournis S., Manoussakis S., Handanis S., Zairis M., Dadiotis L., Foussas S. The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin. Cardiol. 23:2000;160-164.
32. Morrissey C., Lakins J., Moquin A., Hussain M., Tenniswood M. An antigen capture assay for the measurement of serum clusterin concentrations. J. Biochem. Biophys. Meth. 48:2001;13-21.
33. Napoli C., de Nigris F., Palinski W. Multiple role of reactive oxygen species in the arterial wall. J. Cell Biochem. 82:2001;674-682.
34. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow C.C., Cardinez C.J., Castellani L.W., Brennan M.-L., Lusis A.J., Fogelman A.M. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 99:1997;2005-2019.
35. Petropoulou C., Trougakos I.P., Kolettas E., Toussaint O., Gonos E.S. Clusterin/apolipoprotein J is a novel biomarker of cellular senescence, that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett. 509:2001;287-297.
36. Poon S., Easterbrook-Smith S.B., Rybchyn M.S., Carver J.A., Wilson M.R. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry. 39:2000;15953-15960.
37. Reaven P.D., Napoli C., Merat S., Witztumc J.L. Lipoprotein modification and atherosclerosis in aging. Exp. Gerontol. 34:1999;527-537.
38. Rosenberg M.E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int. J. Biochem. Cell Biol. 27:1995;633-645.
39. Silkensen J.R., Hirsch A.T., Lunzer M.M., Chmielewski D., Manivel J.C., Muellerleile M.R., Rosenberg M.E. Temporal induction of clusterin in the peri-infarct zone after experimental myocardial infarction in the rat. J. Lab. Clin. Med. 131:1998;28-35.
40. de Silva H.V., Stuart W.D., Duvic C.R., Wetterau J.R., Ray M.J., Ferguson D.G., Albers H.W., Smith W.R., Harmony J.A.K. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265:1990;13240-13247.
41. Steg P.G., Karila-Cohen D., Feldman L.J. The coronary atherosclerosis of the diabetic. Arch. Mal. Coeur. Vaiss. 93:2000;19-24.
42. Stone D.J., Rozovsky I., Morgan T.E., Anderson C.P., Lopez L.M., Shick J., Finch C.E. Effects of age on gene expression during estrogen-induced synaptic sprouting in the female rat. Exp. Neurol. 165:2000;46-57.
43. Tegos T.J., Kalodiki E., Sabetai M.M., Nicolaides A.N. The genesis of atherosclerosis and risk factors: a review. Angiology. 52:2001;89-98.
44. Trougakos I.P., Gonos E.S. Clusterin/apolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 34:2002;1430-1448.
45. Urbich C., Fritzenwanger M., Zeiher A.M., Dimmeler S. Laminar shear stress upregulates the complement-inhibitory protein clusterin. A novel potent defense mechanism against complement-induced endothelial cell activation. Circulation. 101:2000;352-355.
46. Väkenä A., Laurila P., Meri S. Co-deposition of clusterin with the complement membrane attack complex in myocardial infarction. Immunology. 80:1993;177-182.
47. Viger R.S., Robaire B. Gene expression in the aging brown Norway rat epididymis. J. Androl. 16:1995;108-117.
48. Wilson M.R., Easterbrook-Smith S.B. Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. 25:2000;95-98.
49. Witte D.P., Aronow B.J., Stauderman M.L., Stuart W.D., Clay M.A., Gruppo R.A., Jenkins S.H., Harmony J.A. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein atheromatous lesions. Am. J. Pathol. 143:1993;763-773.
50. Wong P., Taillefer D., Lakins J., Pineault J., Chader G., Tenniswood M. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur. J. Biochem. 221:1994;917-925.